Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
斯文败类的应助被悦耳亦云采纳,获得10
刚刚
qin202569发布了新的文献求助10
刚刚
傲娇的之玉完成签到,获得积分20
2秒前
星辰大海的应助被未见山采纳,获得10
3秒前
悦耳代秋发布了新的文献求助10
3秒前
Akim的应助被曾经夏山采纳,获得10
4秒前
eily完成签到 ,获得积分10
5秒前
5秒前
5秒前
6秒前
小蘑菇的应助被蜜儿采纳,获得10
6秒前
7秒前
丰富的小不完成签到,获得积分10
7秒前
哭泣青烟发布了新的文献求助10
8秒前
8秒前
8秒前
科研通AI6.4的应助被糯糯采纳,获得10
8秒前
慕青的应助被Rui采纳,获得10
8秒前
雷红完成签到,获得积分10
8秒前
8秒前
mqw发布了新的文献求助10
10秒前
12秒前
12秒前
123完成签到,获得积分20
12秒前
yanj520925发布了新的文献求助10
12秒前
煎饼狗子发布了新的文献求助20
12秒前
学习发布了新的文献求助10
13秒前
上杉绘梨衣完成签到,获得积分10
13秒前
情怀的应助被悦耳代秋采纳,获得10
13秒前
斯文败类的应助被悦耳代秋采纳,获得10
13秒前
13秒前
Richard_M的应助被悦耳代秋采纳,获得10
13秒前
华仔的应助被悦耳代秋采纳,获得10
14秒前
14秒前
悦耳亦云发布了新的文献求助10
14秒前
窦窦发布了新的文献求助10
14秒前
阿秒完成签到 ,获得积分10
15秒前
1700360436完成签到 ,获得积分10
16秒前
慕青的应助被微笑尔岚采纳,获得10
16秒前
neuro1993发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Exploring Mental Health in Education 600
Stochastic Models in Operations Research,Vol. 2 600
Organizational Behavior 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8048096
求助须知:如何正确求助?哪些是违规求助? 9477898
关于积分的说明 21290706
捐赠科研通 7614076
什么是DOI,文献DOI怎么找? 3392665
关于科研通互助平台的介绍 2523934
邀请新用户注册赠送积分活动 2430717